Variations in novel cellular therapy products manufacturing

Area of Science:

• Cellular therapy
• Transfusion medicine
• Transplantation

Background:

• The field of cellular therapy is rapidly emerging at the intersection of transfusion medicine and transplantation.
• Current production of novel cellular therapy products often lacks standardization across global cell processing centers.
• Investigational protocols are commonly used, leading to variability in manufacturing practices.

Purpose of the Study:

• To identify and characterize variations in manufacturing practices for similar cellular therapy products across different international cell processing laboratories.
• To assess the extent of standardization in the production of novel cell-based therapies.

Main Methods:

• An exploratory survey was distributed to directors of cell processing laboratories worldwide.
• The survey focused on the manufacturing lifecycle: collection, purification, in vitro expansion, freezing, storage, thawing, and washing.
• The questionnaire also inquired about the regulatory compliance levels for different product types.

Main Results:

• Hematopoietic progenitor cells (HPCs) were the most commonly processed, followed by lymphocytes, mesenchymal stromal cells, dendritic cells, and natural killer (NK) cells.
• A minority of centers processed pancreatic islet cells, neural cells, and induced-pluripotent stem cells.
• Significant variations were observed in purification methods and environmental monitoring practices, differing by product type and institution.

Conclusions:

• This survey reveals substantial heterogeneity in cellular therapy manufacturing processes globally.
• Understanding the impact of these manufacturing variations on cell-based therapy quality is crucial for further process evaluation and development.
• Standardization efforts are needed to ensure consistent and reliable cellular therapy production.